Comprehensive genomic profiling-guided treatment selection in appendiceal adenocarcinoma with discordant mismatch repair findings: a case report and literature review
This case report demonstrates that in a young patient with advanced appendiceal adenocarcinoma and discordant mismatch repair findings, integrating comprehensive genomic profiling with immunohistochemistry and MSI/TMB results was crucial for identifying a germline TP53 variant and guiding the successful selection of anti-EGFR therapy over immunotherapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer treatment has entered an era where doctors look not just at the shape of a tumor under a microscope, but at the specific instructions written inside its cells. For many cancers, the standard approach involves checking a few key markers to decide which drug might work best. One such marker is a system called mismatch repair, which acts like a spell-checker for DNA, fixing errors as cells divide. When this system breaks down, the tumor often accumulates many mistakes, a state that can make it vulnerable to a type of therapy known as immunotherapy, which trains the body's own immune system to attack the cancer. However, biology is rarely simple. Sometimes, a tumor looks like it has a broken spell-checker, yet the actual count of DNA errors remains low, creating a confusing picture for doctors trying to choose a life-saving treatment. This uncertainty is especially difficult when the cancer is rare, as there are fewer established rules to follow.
A recent case report from the University of Toyama illustrates how modern genetic testing can resolve these contradictions. The story centers on a twenty-five-year-old woman who arrived at a hospital with severe abdominal swelling and pain. Scans revealed large masses on her ovaries and widespread cancer throughout her abdomen. Initially, the medical team suspected a primary ovarian cancer, a common diagnosis for such symptoms in young women. However, a biopsy of a small lesion near the appendix told a different story. The cells were a rare and aggressive type known as signet-ring cell adenocarcinoma, originating from the appendix rather than the ovaries. This diagnosis was critical because the standard treatments for ovarian cancer would likely fail, while the approach for this specific type of gastrointestinal cancer required a different strategy.
The medical team faced an immediate and perplexing dilemma. Tests on the tumor tissue showed that the proteins responsible for the DNA spell-checker system were missing, a finding that typically signals the cancer should respond well to immunotherapy. Based on this result, the doctors began a treatment combining two powerful immune drugs. Yet, the patient did not improve; her fluid buildup continued to worsen, and the cancer progressed. The team then turned to a more detailed analysis called comprehensive genomic profiling. This advanced test reads the entire genetic code of the tumor to count the actual number of errors and look for other specific drivers of the disease. The results were surprising: despite the missing spell-checker proteins, the tumor had a very low number of DNA errors and was stable, not the chaotic, error-filled state that usually responds to immunotherapy. The initial test had been misleading.
Armed with this new, more accurate picture, the doctors re-evaluated the patient's options. The genomic profile showed that the tumor did not have the specific genetic mutations that usually block the effectiveness of a different class of drugs called anti-EGFR therapies. These drugs work by blocking a signal that tells cancer cells to grow. Because the tumor lacked the resistance markers that would make these drugs useless, the team added an anti-EGFR antibody to a standard chemotherapy regimen. The change in strategy worked. The patient's symptoms improved dramatically, the fluid in her abdomen disappeared, and scans showed the tumors shrinking. She achieved a significant response and maintained control of the disease for an extended period.
Beyond guiding the treatment, the deep genetic scan uncovered a hidden truth about the patient's health that went beyond the cancer itself. The test identified a specific error in a gene called TP53 that was present in her normal cells as well as her tumor cells. This finding pointed to a hereditary condition known as Li-Fraumeni syndrome, a genetic predisposition that increases the risk of developing various types of cancer. The patient had no family history of this syndrome, suggesting she had developed the genetic error spontaneously. This discovery was vital, not only for her own long-term care but also for her family, as it allowed them to understand their own risks and seek appropriate screening.
This case highlights a crucial lesson for the future of cancer care. Relying on a single test can sometimes lead doctors down the wrong path, especially with rare tumors where the rules are not yet fully written. By combining different types of genetic information, doctors can see the full picture, avoiding treatments that will not work and finding those that will. It also demonstrates that looking deeply into a tumor's genetics can reveal life-changing information about a patient's inherited health risks, turning a single diagnosis into a broader opportunity for prevention and care. In the complex world of rare cancers, this integrated approach offers a clearer path forward when the standard signs are unclear.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.